OR WAIT null SECS
November 15, 2017
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
November 11, 2017
This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
October 16, 2017
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
October 12, 2017
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.
October 04, 2017
Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.
September 14, 2017
Shingrix represents a new, possibly better alternative to existing treatments.
June 22, 2017
A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.
April 12, 2017
The agency issued its recommendation for the influenza virus strains European vaccine manufacturers should include for 2017.